COVID-19 Response: Supporting the frontline

Updated 7/13/2020 In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19, a disease caused by a novel strain of...
Read More
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
America’s biopharmaceutical companies are working around the clock to beat coronavirus

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) underscored the industry’s commitment to finding solutions to prevent,...
Read More
Guest post: Takeda’s efforts to address COVID-19

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest ...
Read More
ICYMI: America’s biopharmaceutical companies are taking on COVID-19

The biopharmaceutical industry is taking on COVID-19, a disease caused by a novel strain of coronavirus, through research and development (R&D) into prevention and treatment, in-kind financial...
Read More
PhRMA submits comments on FDA’s proposed rule on drug importation

Yesterday, PhRMA submitted comments in response to the Food and Drug Administration’s proposed rule, “Importation of Prescription Drugs.” As PhRMA President and CEO Stephen J. Ubl stated when the...
Read More
Nearly 400 cell and gene therapies in development to target a broad range of diseases

In 2017, the U.S. approved its first cell and gene therapy, making the idea of altering a gene to cure or treat a disease a reality. As the increasing pace of R&D propels cell and gene therapy...
Read More
ICYMI: Continued biopharmaceutical action on COVID-19

Updated 3/11/2020 This week, PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss the industry’s response to COVID-19, a...
Read More
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt patients’ ability to...
Read More